| If this is not your name, click here. | | |
| | Contact Us | Order Now | Journals | Bookstore | Register a colleague | | |
| | | ![]() Axert (Almotriptan Malate) Relieves Migraine With Fewer Side Effects than Imitrex (Sumatriptan Succinate) WELLESLEY HILLS, MA -- May 8, 2001 -- Throbbing, disabling headaches are nothing new for 28 million people suffering from migraine -- mostly 25 to 55 year-old women. And for many sufferers, side effects of treatment may be as bad as the headache itself. Research shows a new migraine treatment is highly effective, comparable to the most commonly prescribed medication in its class, but with fewer side effects. The comparison study of Axert™ (almotriptan malate) tablets, a newly approved anti-migraine medication, and Imitrex® (sumatriptan succinate) tablets was conducted by Boston Clinical Research Center in Wellesley Hills, Massachusetts. In a double-blind study, patients receiving Axert 12.5 mg for moderate or severe migraine headache showed similar pain relief at two hours to patients receiving sumatriptan 50 mg. However, patients taking Axert reported significantly fewer side effects compared to the sumatriptan-treated group -- particularly less chest pain. SOURCE: Boston Clinical Research Center
|